CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
Dasatinib +2 moredrug
Likely dose
Dasatinib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00339144
NCT00339144Phase 1Completed
CompareCT.gov

A Phase I Study of BMS-354825 in Patients With Solid Tumors

Bristol-Myers Squibb·interventional·Posted Jun 20, 2006·Updated Dec 15, 2010

In Brief

A Phase 1 clinical trial evaluating Dasatinib for Tumors. Completed, enrolled 16 participants across 2 sites.

Detailed Summary

The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTumors
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 20, 2006
Enrollment StartJan 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 20.0 years ago

Interventions

Dasatinibdrug

tablets, Oral, 100 mg, once daily for 4 weeks

Dasatinibdrug

tablets, Oral, 150 mg, once daily, 4 weeks

Dasatinibdrug

tablets, Oral, 200 mg, once daily for 4 weeks